Kanghong Pharmaceutical announced that the Drug Evaluation Center of the State Drug Administration agreed to accept the application for KH631 clinical trials submitted by Hongji Biology, a subsidiary of the company. KH631 ophthalmic injection is a kind of new biological drug with independent intellectual property rights, which is used to deliver target genes through adeno-associated virus (AAV) for the treatment of neovascular (wet) age-related macular degeneration (nAMD).
康弘药业：子公司药品临床试验申请获受理
Kanghong Pharmaceutical Co., Ltd.: application for clinical trials of subsidiary drugs accepted
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.